Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-024-03906-z ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yun Qiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang,The Affiliated Lianyung…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Province Key Research and Development Plan (Social Development) Project.
Abstract (Originalsprache)
BACKGROUND: Due to its strong immunogenicity and tumor specificity, neoplastic antigen has emerged as an immunotherapy target with wide therapeutic prospect and clinical application value. Anti-programmed death-1 (PD-1) antibodies reinvigorate T cell-mediated antitumor immunity. So, we conducted single-arm trial to assess the safety and efficacy of PD-1 blockade(Camrelizumab)-activated neoantigen specific cellular therapy (aNASCT) on advanced relapsed non-small lung cancer(NSCLC)(ClinicalTrials.gov NCT03205930). METHODS: Neoantigenic peptides were designed and manufactured according to the whole exome sequencing and RNA sequencing of fresh biopsy tissues and peripheral blood as well as bioinformatics analysis. All participants received subcutaneous injection of mature dendritic cells(mDCs) loaded with neoantigens on day 8 and an intravenous infusion of PD-1 blockade-activated autologous cytotoxic T lymphocytes (CTLs) induced by mDCs on day 27 for a period defined as 28 days (4 weeks). Enrolled patients received at least three cycles of therapy. The safety and efficacy of the treatment were evaluated by evaluating adverse reactions, progression-free survival (PFS), overall survival (OS). RESULTS: A total of 13 patients with advanced relapsed NSCLC were enrolled in this study. All 13 patients received at least three cycles of aNASCT treatment, of which two patients received at most 12 cycles of treatment. Treatment-related adverse events (AEs) occurred in 4/13 (30.8%)patients with transient fever below 38℃.The objective response rate (ORR) across the 13 enrolled patients was 7 of 13 (53.85%,95% CI 0.29-0.77).The disease control rate (DCR) was 8 of 13 (61.54%,95% CI 0.36-0.82). The median PFS was 11 months (95% CI 6.1-15.9), and the median OS was 15 months(95% CI 11.5-18.5). CONCLUSIONS: Our findings indicate that aMASCT therapy was safety and immunogenicity of patients with advanced relapsed NSCLC, suggesting its promising potential in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang,The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, 222002, China.
- Department of Precision Medicine Laboratory, Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang,The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyu…
- Department of Oncology, Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang,The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, 222002, China.…
Förderung
- Jiangsu Province Key Research and Development Plan (Social Development) Project
Zitieren
APA
Qiao, Y., Hui, K., Hu, C., Wang, M., Sun, W., Liu, L., Dong, C., & Jiang, X. (2025). Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03906-z
Vancouver
Qiao Y, Hui K, Hu C, Wang M, Sun W, Liu L, et al. Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03906-z
BibTeX
@article{Qiao2025,
author = {Qiao, Yun and Hui, Kaiyuan and Hu, Chenxi and Wang, Mei and Sun, Wen and Liu, Liang and Dong, Changhong and Jiang, Xiaodong},
title = {Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-024-03906-z}
}
EUVIMED